Baris E, McGregor M
Département d'Administration de la santé, Université de Montréal, Que.
CMAJ. 1993 Jan 15;148(2):175-83.
To evaluate the safety and potential cost savings of hemodialyzer reuse.
All English and French articles published from 1960 to 1991 related to hemodialyzer reuse (retrieved through an Index Medicus and MEDLINE search [corrected]), the indexes of eight North American journals from 1960 onward, conference proceedings, association guidelines, and US and Canadian laws and regulations.
For health care personnel the reuse of hemodialyzers did not entail any increased risk of infection or exposure to toxic substances if proper control measures were taken. For patients there was no evidence to suggest any excess risk of complications or death as long as precise and appropriate procedures are observed. The "first-use syndrome" can be prevented and should no longer be considered as a reason to favour reuse. A cost-minimization analysis indicated that five uses might save up to $3629 per patient yearly. Thus, the adoption of a policy of reuse in Canada for all eligible patients undergoing long-term hemodialysis could result in direct savings of about $5.8 to $8.9 million per year.
The health risks associated with hemodialyzer reuse can be reduced to acceptable levels through the rigorous observance of proper quality-assurance and quality-control measures and the use of automated reconditioning equipment. Such a policy could achieve modest savings for the health care system. A decision to reuse should be formally adopted by the institution and accompanied by a precise definition of the standards of quality assurance and control.
评估血液透析器复用的安全性及潜在的成本节约情况。
1960年至1991年发表的所有与血液透析器复用相关的英文和法文文章(通过医学索引和MEDLINE检索[校正后]获取)、1960年起八本北美期刊的索引、会议论文集、协会指南以及美国和加拿大的法律法规。
对于医护人员而言,如果采取适当的控制措施,复用血液透析器不会增加感染风险或接触有毒物质的风险。对于患者,只要遵循精确且恰当的程序,没有证据表明会有任何额外的并发症风险或死亡风险。“首次使用综合征”是可以预防的,不应再被视为支持复用的理由。成本最小化分析表明,复用五次每年可为每位患者节省多达3629美元。因此,在加拿大对所有符合条件的长期血液透析患者采用复用政策,每年可直接节省约580万至890万美元。
通过严格遵守适当的质量保证和质量控制措施以及使用自动化修复设备,与血液透析器复用相关的健康风险可降低至可接受水平。这样的政策可为医疗保健系统实现适度的节约。复用决策应由机构正式做出,并伴有质量保证和控制标准的精确定义。